JYMed Technology Co., Ltd. yasangalala kulengeza kuti katundu wake, Tirzepatide, amaliza bwino kulembetsa Drug Master File (DMF) ndi US FDA (DMF Number: 040115) ndipo adalandira Chivomerezo cha FDA pa Ogasiti 2, 2024.
Mass Production yokhala ndi Stable Quality
Malinga ndi oyang'anira akuluakulu a JYMed Technology, kupanga zochuluka kwa Tirzepatide Active Pharmaceutical Ingredient (API) kumatha kufika pa kilogalamu. Magulu opangira ndi okhazikika komanso opitilira, ndipo amasiyana pang'ono pakati pa magulu, kuwonetsetsa kuti zikhala bwino.
Zotsatira zazikulu pa Glucose ndi Kuchepetsa Lipid
Tirzepatide ndiye woyamba kuvomerezedwa kamodzi pa sabata GIP/GLP-1 receptor agonist. Monga dual receptor agonist, nthawi imodzi imatha kumanga ndi kuyambitsa ma receptor omwe amadalira glucose-insulinotropic polypeptide (GIP) ndi GLP-1 receptor m'thupi la munthu. Kuphatikiza pakuchepetsa kuchuluka kwa shuga, imachepetsa kudya, kulemera kwa thupi, ndi mafuta, ndikuwongolera kagwiritsidwe ntchito ka lipid. Kupitilira pazotsatira zake zazikulu zochepetsera shuga komanso kuchepetsa thupi, kuwunika kwamagulu ang'onoang'ono kuchokera ku kafukufuku wamtundu wa SURPASS wawonetsa kuti Tirzepatide imathandiziranso zizindikiro za metabolic monga kuthamanga kwa magazi, lipids wamagazi, BMI, ndi chiuno.
Kuvomerezedwa ndi Mayiko Amitundu Yambiri ndi Zoyembekeza Zolonjeza
Malinga ndi chidziwitso chofunikira, Mounjaro yotsitsa shuga idavomerezedwa koyamba ndi US FDA mu Meyi 2022 kuti azichiza akuluakulu omwe ali ndi matenda a shuga a 2. Pambuyo pake idalandira zovomerezeka ku EU, Japan, ndi zigawo zina. Mu Novembala 2023, a FDA adavomerezanso chizindikiritso chochepetsa thupi pansi pa dzina la Zepbound. Mu Meyi 2024, idalowa bwino pamsika waku China. Poganizira kuchuluka kwa momwe angagwiritsire ntchito komanso zambiri zothandizira kafukufuku, Tirzepatide yakhala imodzi mwamankhwala otchuka kwambiri a peptide masiku ano. Kugulitsa kwake kudafika $ 5.163 biliyoni mu 2023, ndipo kotala yoyamba ya 2024 yokha idagulitsa $ 2.324 biliyoni, kuwonetsa kukula kodabwitsa.
Za JYMed
Shenzhen JYMed Technology Co., Ltd. (yomwe tsopano imatchedwa JYMed) idakhazikitsidwa mu 2009, ikuchita kafukufuku, chitukuko, kupanga, ndi malonda a peptides ndi zinthu zokhudzana ndi peptide. Ndi malo amodzi ofufuzira komanso maziko atatu opangira, JYMed ndi amodzi mwa omwe amapanga ma API a peptide opangidwa ndi mankhwala ku China. Gulu lalikulu la R&D la kampaniyo limadzitamandira kwazaka zopitilira 20 pantchito ya peptide ndipo ladutsa bwino pakuwunika kwa FDA kawiri. Dongosolo lambiri komanso logwira mtima la ma peptide la JYMed limapatsa makasitomala ntchito zambiri, kuphatikiza kupanga ndi kupanga ma peptides achire, ma peptides anyama, antimicrobial peptides, ndi cosmetic peptides, komanso kulembetsa ndi kuthandizira pakuwongolera.
Zochita Zazikulu Zamalonda
1.Kulembetsa kwapakhomo komanso kumayiko ena kwa ma peptide API
2.Veterinary and cosmetic peptides
3.Custom peptides ndi CRO, CMO, OEM misonkhano
4.PDC mankhwala (peptide-radionuclide, peptide-yaing'ono molekyulu, peptide-mapuloteni, peptide-RNA)
Kuphatikiza pa Tirzepatide, JYMed yatumiza zolemba zolembetsa ndi FDA ndi CDE pazinthu zina zingapo za API, kuphatikiza mankhwala odziwika bwino a GLP-1RA monga Semaglutide ndi Liraglutide. Makasitomala amtsogolo omwe akugwiritsa ntchito zinthu za JYMed azitha kulozera mwachindunji nambala yolembetsa ya CDE kapena nambala ya fayilo ya DMF potumiza mafomu olembetsa ku FDA kapena CDE. Izi zidzachepetsa kwambiri nthawi yofunikira pokonzekera zikalata zofunsira, komanso nthawi yowunikira komanso mtengo wowunikiranso zinthu.
Lumikizanani nafe
Malingaliro a kampani Shenzhen JYMed Technology Co., Ltd.
Adilesi:8th & 9th Floors, Building 1, Shenzhen Biomedical Innovation IndustrialPark, No. 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen
Foni:+ 86 755-26612112
Webusaiti: http://www.jymedtech.com/
Nthawi yotumiza: Aug-12-2024